What does an eGFR of 48 mL/min/1.73 m² indicate and how should it be managed?

eGFR 48: Stage 3a Chronic Kidney Disease Requiring Immediate Intervention

An eGFR of 48 mL/min/1.73 m² indicates Stage 3a chronic kidney disease (CKD), and you must initiate kidney-protective therapies immediately, specifically SGLT2 inhibitors and RAS inhibitors, while investigating the underlying cause and assessing albuminuria to guide further management.

What This Number Means

Your patient has moderate CKD with reduced kidney function. An eGFR of 48 places them in the G3a category (eGFR 45-59 mL/min/1.73 m²), representing a significant decline from normal kidney function (>90 mL/min/1.73 m²) 1.

Critical caveat: eGFR equations consistently overestimate true kidney function, particularly near clinically important thresholds. Studies show eGFR may overestimate measured GFR by 8-13 mL/min/1.73 m² at this level 2. Your patient's actual kidney function may be closer to 35-40 mL/min/1.73 m², approaching Stage 3b CKD.

Immediate Diagnostic Steps

1. Measure Urine Albumin-to-Creatinine Ratio (ACR)

This is non-negotiable. The presence and degree of albuminuria completely changes management:

• ACR <30 mg/g (A1): Normal to mildly increased
• ACR 30-300 mg/g (A2): Moderately increased
• ACR >300 mg/g (A3): Severely increased

2. Confirm CKD Chronicity

Repeat eGFR and ACR in 3 months to confirm this is chronic (>3 months duration) rather than acute kidney injury.

3. Identify Underlying Cause

Check for:

• Diabetes (HbA1c)
• Hypertension (blood pressure)
• Urinalysis (hematuria, proteinuria pattern)
• Renal ultrasound (obstruction, structural abnormalities)

Pharmacologic Management Algorithm

Step 1: Start SGLT2 Inhibitor (Highest Priority)

For eGFR 20-45 mL/min/1.73 m² with ACR <200 mg/g: Start SGLT2i (Grade 2B recommendation) 1

For eGFR ≥20 mL/min/1.73 m² with ACR ≥200 mg/g OR heart failure: Start SGLT2i (Grade 1A recommendation) 1

For Type 2 diabetes with eGFR ≥20: Start SGLT2i (Grade 1A recommendation) 1

At eGFR 48, your patient qualifies for SGLT2i therapy regardless of diabetes status if they have:

• ACR ≥200 mg/g, OR
• Heart failure, OR
• Even ACR <200 mg/g (though this is a weaker 2B recommendation)

Key practice points:

• Continue SGLT2i even if eGFR drops below 20 during treatment 1
• Expect a reversible eGFR dip initially—this is NOT a reason to stop 1
• Withhold during prolonged fasting, surgery, or critical illness (ketosis risk) 1

Step 2: Start or Continue RAS Inhibitor (ACEi or ARB)

If ACR ≥300 mg/g (A3): Start RASi regardless of diabetes status (Grade 1B) 1

If ACR 30-300 mg/g (A2) with diabetes: Start RASi (Grade 1B) 1

If ACR 30-300 mg/g (A2) without diabetes: Consider RASi (Grade 2C) 1

Dosing strategy:

• Use the highest approved tolerated dose—benefits in trials were achieved at maximum doses 1
• Check BP, creatinine, and potassium 2-4 weeks after initiation or dose increase 1

When to continue despite concerns:

• Continue RASi even when eGFR falls below 30 mL/min/1.73 m² 1
• Continue unless creatinine rises >30% within 4 weeks 1
• Manage hyperkalemia with potassium-lowering strategies rather than stopping RASi 1

When to reduce or stop:

• Symptomatic hypotension
• Uncontrolled hyperkalemia despite medical management
• eGFR <15 with uremic symptoms 1

Step 3: Consider Nonsteroidal MRA (If Type 2 Diabetes)

If Type 2 diabetes, eGFR >25, normal potassium, and ACR >30 mg/g despite maximum RASi: Add nonsteroidal MRA like finerenone (Grade 2A) 1

Dosing based on potassium 1:

• K+ ≤4.8 mmol/L: Start finerenone 10 mg daily (eGFR 25-59) or 20 mg daily (eGFR ≥60)
• K+ 4.9-5.5 mmol/L: Continue current dose, monitor K+ every 4 months
• K+ >5.5 mmol/L: Hold finerenone, address hyperkalemia, recheck before restarting

This can be added on top of both SGLT2i and RASi 1.

Monitoring Schedule

Every 2-4 weeks initially (when starting/adjusting RASi):

• Serum creatinine/eGFR
• Serum potassium
• Blood pressure

Every 3-4 months once stable:

• eGFR and ACR
• Electrolytes
• Blood pressure

Every 6 months:

• Screen for malnutrition (if age >65 or symptomatic) 3
• Assess uremic symptoms using validated tools 3

When to Refer to Nephrology

Refer immediately if 3:

• eGFR <30 mL/min/1.73 m² (approaching Stage 4)
• ACR >300 mg/g (severely increased albuminuria)
• Sustained eGFR decline >5 mL/min/year
• Persistent hematuria
• Uncontrolled hypertension despite multiple agents
• Hyperkalemia >5.5 mmol/L despite management
• Uncertain etiology of CKD

At eGFR 48, you don't need immediate nephrology referral if the cause is clear (diabetes, hypertension) and you're comfortable initiating kidney-protective therapies. However, if eGFR continues declining or albuminuria is severe, refer promptly.

Critical Medication Safety Considerations

Avoid nephrotoxic agents:

• NSAIDs (major risk factor for further decline)
• Aminoglycosides
• High-dose or repeated contrast dye (even at eGFR 48, risk exists) 4

Adjust medications for renal function:

• Many drugs require dose adjustment at eGFR <60
• Metformin: Generally safe at eGFR 45-60, but hold during acute illness 3
• Consider pharmacist consultation for complex regimens 3

Contrast procedures:

• At eGFR 48, contrast-induced AKI risk is elevated even though eGFR >45 4
• Ensure adequate hydration before contrast studies
• Consider alternative imaging when possible

Bottom Line Treatment Algorithm

1. Measure ACR immediately (determines treatment intensity)
2. Start SGLT2 inhibitor (nearly all patients at eGFR 48 qualify)
3. Start/optimize RAS inhibitor (if ACR ≥30 mg/g or other indications)
4. Add nonsteroidal MRA (if Type 2 diabetes with persistent albuminuria on RASi)
5. Monitor closely (creatinine, potassium, BP at 2-4 weeks)
6. Refer to nephrology (if eGFR continues declining or ACR >300)

The goal is to slow progression and prevent cardiovascular events—both SGLT2i and RASi reduce mortality and kidney failure risk when started at this stage 1.